JERUSALEM, November 15 (Xinhua) – In a report published by the Tel Aviv University on Thursday, Israeli researchers developed a treatment that could prevent developmental decline and autism.
Researchers have found that early treatment with peptide NAP (nucleosome montage protein) normalizes the development of mice in a model of ADNP (activity-dependent neuroprotective protein) syndrome in children.
This genetic mutation is one of the main causes of developmental delay and autism in children.
The ADNP gene is involved in the development of cognition. Embryos with partial ADNP deficiency will suffer from mental retardation and, in most cases, autism.
In recent years, with the development of genetic sequencing technology, there have been random mutations in the ADNP gene during pregnancy during autistic children with mental retardation.
The resulting protein is shorter than normal and as a result, children suffer from incomplete ADNP (ADNP syndrome).
The researchers found that according to the report, mice with ADNP produce about half of the number of synapses (the points of contact between nerve cells) in brain regions that are responsible for cognitive activity, especially when compared to healthy mice.
These mice showed developmental delay, social difficulty and sensitivity as children with mental retardation and autism.
In the next step, the NAP peptide was injected daily to the affected mice from birth, followed by nasal spray fed to the breast-fed mice.
The results were very impressive: the treated mice developed normally, unlike the untreated mice. They searched their mothers, walked, had the right memories, were able to distinguish between familiar and unfamiliar mice and developed strength in their muscles.
In addition, it was found that the brains of these mice began to produce the appropriate number of synapses.